Bard To Pay $51 Million To Settle Old Whistleblower Claim
C.R. Bard, Inc. (“Bard”) will pay just shy of $51 million to the Government and a former employee-turned whistleblower over allegations that the New Jersey medical device giant overbilled Medicare from...
View ArticleForm Over Substance: Bausch + Lomb’s ISTA Pharmaceuticals Unit Settles with U.S
ISTA Pharmaceuticals, Inc. (“ISTA”), a unit of eye care giant Bausch + Lomb (“B&L”), recently agreed to a $33.5 million Government settlement involving civil and criminal charges. The conduct...
View ArticleFalse Claims Act Cases Based on GMP Violations . . . Watch Out For...
It they haven’t already started, pharmaceutical manufacturers should be re-assessing their compliance with all aspects of FDA “current Good Manufacturing Practices” (“GMPs”), given the agency’s focus...
View ArticlePfizer $149 Million Rapamune Settlement Is More Proof That It’s Business As...
Two False Claims Act whistleblower lawsuits are being resolved as part of a $491 million settlement between Wyeth Pharmaceuticals, now a division of Pfizer, Inc., and the U.S. DOJ. This time around,...
View ArticleBoston Scientific Battles Former Employees-Turned Whistleblowers Over “Trade...
In what will likely be another adverse legal decision for Boston Scientific Corporation’s Neuromodulation subsidiary (“BSNC”) in its ongoing battle with two former billing services employees-turned...
View ArticlePlaintiff’s Lawyers File RICO Class Action Suit Against Abbott Over Depakote...
A well-known plaintiff’s law firm with a stable of union pension fund clients has used the Racketeering Influenced and Corrupt Organizations Act (“RICO”), which was originally enacted in 1970 to combat...
View ArticleBig Pharma On Its Heels as China Rounds Up “More Of The Usual Suspects” And...
Allegations of misconduct continue to plague Big Pharma companies in China. Charges of bribery, corruption, off-label promotion, and inflated pricing now extend beyond GlaxoSmithKline (GSK) to...
View ArticleMedtronic InFUSE Cases Signal That Off-Label Promotion Probably Not Illegal
A majority of plaintiffs seeking damages based on off-label promotion of Medtronic’s InFUSE Bone Graft system have been stopped in their tracks following several recent federal court decisions holding...
View ArticleJ&J to Pay $2.2 Billion To End Long-Standing Investigations By Feds
Charges of off-label marketing and kickback payments to physicians and long-term care pharmacy provider Omnicare are behind a $2.2 billion settlement agreement between Johnson & Johnson (“J&J”)...
View ArticleGovernment Slams Ranbaxy Again Over Plant In India
Last week the FDA announced that Ranbaxy’s Toansa plant in India failed inspection — the sixth Ranbaxy plant to cease making drugs for the U.S. market following revelations from a whistleblower that...
View Article